CTLA4 and neoplasm: Using receiver operating characteristic curve (ROC) analysis, we found that the NK cell activation signature had a moderate ability to classify anti-CTLA-4 response (Fig. 4C, AUC = 0.748), suggesting that the NK activation signature has the potential utility to predict responsiveness to anti-CTLA-4 from pre-treatment tumor biopsies.